Protocol for the Delivery of Stem Cells as Trabecular Meshwork
- Authors: Anthonia Okolie1, Ya Fatou Njie Mbye2, Fatima Muili3, Catherine A. Opere4, Sunny E. Ohia5
-
View Affiliations Hide Affiliations1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA 2 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA 3 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA 4 Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, Nebraska, USA 5 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA
- Source: Research Protocols for Ophthalmic Disease Mechanisms and Therapeutics: Glaucoma - Ocular Hypertension , pp 495-500
- Publication Date: August 2025
- Language: English
Protocol for the Delivery of Stem Cells as Trabecular Meshwork, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815324334/chapter-44-1.gif
In this chapter, the protocol for the delivery of stem cells as trabecular meshwork cell replacement therapy is described. There are several types of stem cells that have been investigated in ocular regenerative medicine, such as induced pluripotent stem cells, mesenchymal stem cells, tissue-specific stem cells (progenitor cells), and adipose tissue-derived stem cells. These stem cells have the capacity to differentiate into functional cells and have been used in various ex vivo and animal models of glaucoma to restore intraocular pressure (IOP) homeostasis and trabecular meshwork (TM) cellularity. The protocol provides a series of steps that can serve as a guide for researchers in the production and use of induced pluripotent stem cells (iPSCs) as cell replacement therapy for the TM, which is damaged and/or lost due to ocular hypertension-induced glaucomatous condition.
-
From This Site
/content/books/9789815324334.chapter-44dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
